Crinetics Pharmaceuticals, Inc. (CRNX) Insider Trading
Over the last 3 months, CRNX insiders made 0 open-market buys and 3 sales, a net sale of -$3.6M (SEC Form 4). Over the last 6 months, 227 institutions increased and 134 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
3
Net (3m)
-$3.6M
Insider trades by month Buys Sells
Oct
Nov
Dec
Jan
Mar
Apr
Context3-month price -11%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 10, 2026 | Knight Jeff E.officer: Chief Dev. & Operating Officer | Option | 19,336 | $19.64 |
| Apr 10, 2026 | Knight Jeff E.officer: Chief Dev. & Operating Officer | Sell | 85,163 | $40.10 |
| Apr 10, 2026 | Knight Jeff E.officer: Chief Dev. & Operating Officer | Option | 9,624 | $20.02 |
| Apr 10, 2026 | Knight Jeff E.officer: Chief Dev. & Operating Officer | Option | 49,474 | $23.98 |
| Mar 13, 2026 | Vivaldi Coelho Rogeriodirector | Sell | 523 | $36.77 |
| Mar 13, 2026 | Vivaldi Coelho Rogeriodirector | Sell | 4,477 | $36.08 |
| Mar 4, 2026 | Schilke Tobinofficer: Chief Financial Officer | Sell | 6,713 | $39.67 |
| Mar 4, 2026 | Okey Stephaniedirector | Sell | 3,000 | $39.67 |
| Feb 25, 2026 | Schilke Tobinofficer: Chief Financial Officer | Grant | 50,000 | $43.79 |
| Feb 25, 2026 | Betz Stephen F.officer: Chief Scientific Officer | Grant | 30,000 | — |
| Feb 25, 2026 | Kalofonos Isabelofficer: Chief Commercial Officer | Grant | 55,000 | $43.79 |
| Feb 25, 2026 | Struthers Richard Scottdirector, officer: President & CEO | Grant | 228,000 | $43.79 |
| Feb 25, 2026 | Knight Jeff E.officer: Chief Operating Officer | Grant | 34,000 | — |
| Feb 25, 2026 | Knight Jeff E.officer: Chief Operating Officer | Grant | 55,000 | $43.79 |
| Feb 25, 2026 | Betz Stephen F.officer: Chief Scientific Officer | Grant | 47,000 | $43.79 |
| Feb 25, 2026 | Kalofonos Isabelofficer: Chief Commercial Officer | Grant | 34,000 | — |
| Feb 25, 2026 | Schilke Tobinofficer: Chief Financial Officer | Grant | 32,000 | — |
| Feb 25, 2026 | Struthers Richard Scottdirector, officer: President & CEO | Grant | 62,000 | — |
| Jan 7, 2026 | Kalofonos Isabelofficer: Chief Commercial Officer | Option | 2,500 | $40.59 |
| Jan 7, 2026 | Kalofonos Isabelofficer: Chief Commercial Officer | Sell | 2,500 | $55.00 |
| Dec 29, 2025 | Betz Stephen F.officer: Chief Scientific Officer | Option | 18,000 | $1.91 |
| Dec 18, 2025 | Struthers Richard Scottdirector, officer: President & CEO | Option | 28,400 | $15.29 |
| Dec 18, 2025 | Struthers Richard Scottdirector, officer: President & CEO | Option | 16,342 | $9.28 |
| Dec 3, 2025 | Pizzuti Danaofficer: Chief Med and Dev Officer | Sell | 5,000 | $45.02 |
| Dec 3, 2025 | Pizzuti Danaofficer: Chief Med and Dev Officer | Option | 5,000 | $16.89 |
| Nov 5, 2025 | Pizzuti Danaofficer: Chief Med and Dev Officer | Sell | 100 | $43.27 |
| Nov 5, 2025 | Pizzuti Danaofficer: Chief Med and Dev Officer | Sell | 4,900 | $42.65 |
| Nov 5, 2025 | Pizzuti Danaofficer: Chief Med and Dev Officer | Option | 5,000 | $16.89 |
| Oct 3, 2025 | Pizzuti Danaofficer: Chief Med and Dev Officer | Option | 5,000 | $16.89 |
| Oct 3, 2025 | Pizzuti Danaofficer: Chief Med and Dev Officer | Sell | 5,000 | $41.81 |
Source: CRNX SEC Form 4 filings, latest Apr 10, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their CRNX positions over the last 6 months (SEC Form 13F).
Increased
227
New positions
92
Reduced
134
Sold out
72
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 15.8M | May 15, 2026 |
| FMR LLC | Increased | 14.3M | Feb 17, 2026 |
| VANGUARD GROUP INC | Reduced | 9.1M | Jan 29, 2026 |
| BLACKROCK, INC. | Increased | 8.5M | May 13, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 8.3M | May 15, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 8.2M | May 15, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 8.0M | Feb 17, 2026 |
| BLACKROCK, INC. | Increased | 8.0M | Feb 12, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 6.9M | Feb 17, 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | Increased | 6.4M | May 15, 2026 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | Reduced | 6.4M | Feb 17, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 5.8M | Feb 17, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 5.4M | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Reduced | 5.2M | Feb 17, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 4.7M | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.